TR200201643T2 - Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. - Google Patents
Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler.Info
- Publication number
- TR200201643T2 TR200201643T2 TR2002/01643T TR200201643T TR200201643T2 TR 200201643 T2 TR200201643 T2 TR 200201643T2 TR 2002/01643 T TR2002/01643 T TR 2002/01643T TR 200201643 T TR200201643 T TR 200201643T TR 200201643 T2 TR200201643 T2 TR 200201643T2
- Authority
- TR
- Turkey
- Prior art keywords
- bone
- osteoporosis
- receptor selective
- methods
- loss
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 101150109738 Ptger4 gene Proteins 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 4
- 210000000988 bone and bone Anatomy 0.000 abstract 4
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 235000019738 Limestone Nutrition 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 230000008468 bone growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000006028 limestone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17135399P | 1999-12-22 | 1999-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200201643T2 true TR200201643T2 (tr) | 2002-11-21 |
Family
ID=22623430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/01643T TR200201643T2 (tr) | 1999-12-22 | 2000-11-20 | Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. |
| TR2003/01841T TR200301841T4 (tr) | 1999-12-22 | 2000-12-11 | Osteoporoz tedavisinde EP4 reseptör seçici. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2003/01841T TR200301841T4 (tr) | 1999-12-22 | 2000-12-11 | Osteoporoz tedavisinde EP4 reseptör seçici. |
Country Status (36)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| EA200300379A1 (ru) | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| JP2004521954A (ja) * | 2001-07-16 | 2004-07-22 | エフ．ホフマン−ラ ロシュ アーゲー | Ｅｐ４受容体作用薬としてのプロスタグランジン類似体 |
| PL215425B1 (pl) * | 2001-07-16 | 2013-12-31 | Ono Pharmaceutical Co | Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie |
| JP4273407B2 (ja) | 2001-07-23 | 2009-06-03 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| JPWO2003041717A1 (ja) * | 2001-11-12 | 2005-03-03 | 小野薬品工業株式会社 | プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤 |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| WO2003047417A2 (en) * | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
| AU2002358772B2 (en) | 2001-12-20 | 2008-11-20 | Merck Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
| AU2003211574A1 (en) | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| EP1490055A1 (en) * | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| EP1513589B1 (en) | 2002-06-06 | 2010-11-10 | Merck Frosst Canada Ltd. | 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma |
| AU2003237520B2 (en) | 2002-06-10 | 2009-01-08 | Laboratoires Serono Sa | Gamma lactams as prostaglandin agonists and use thereof |
| HUE029417T2 (en) | 2002-10-10 | 2017-02-28 | Ono Pharmaceutical Co | Microspheres containing ONO-1301 |
| EP1581503A4 (en) | 2002-11-08 | 2007-07-25 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
| WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| EP1654219A2 (en) * | 2003-07-18 | 2006-05-10 | Applied Research Systems ARS Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
| AU2004268012B2 (en) | 2003-09-02 | 2008-11-20 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| BRPI0414102A (pt) | 2003-09-04 | 2006-10-31 | Merck & Co Inc | composto, uso do mesmo, e, composição |
| US7494983B2 (en) | 2003-09-04 | 2009-02-24 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| US7563816B2 (en) | 2004-07-20 | 2009-07-21 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| WO2006061366A1 (en) | 2004-12-06 | 2006-06-15 | Laboratoires Serono S.A. | Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| EP1878429B1 (en) | 2005-04-28 | 2011-08-03 | Ono Pharmaceutical Co., Ltd. | Trenadermal absorption preparation |
| KR100686186B1 (ko) * | 2005-06-13 | 2007-02-26 | 영진종합건설 주식회사 | 교량용 배수 구조물 |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| US8410171B2 (en) | 2006-10-26 | 2013-04-02 | Ono Pharmaceutical Co., Ltd. | Adhesive preparation |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| US20090124695A1 (en) | 2007-11-14 | 2009-05-14 | Cayman Chemical Company | Prostaglandin e1 and e2 analogs for the treatment of various medical conditions |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| US9682065B2 (en) | 2011-08-02 | 2017-06-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| EP2875022B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| PT2989098T (pt) * | 2013-03-15 | 2017-08-16 | Cayman Chemical Co Inc | Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4 |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| CN105392505A (zh) | 2013-07-19 | 2016-03-09 | 开曼化学股份有限公司 | 用于促进骨生长的方法、系统和组合物 |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR897566A (fr) | 1942-08-28 | 1945-03-26 | Bopp & Reuther Gmbh | Machine à rotors |
| US3528961A (en) | 1966-08-16 | 1970-09-15 | Allied Chem | Monoazo dyes from e-caprolactam |
| US3780095A (en) | 1970-04-08 | 1973-12-18 | Byk Gulden Lomberg Chem Fab | Acylated anilino-carboxylic acids and their salts |
| US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| SE7414770L (enExample) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
| DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
| US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
| US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| DE2528664A1 (de) * | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
| US4243678A (en) | 1977-12-30 | 1981-01-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Acylhydrocarbylaminoalkanoic acids, compositions and uses |
| DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3042482A1 (de) | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3266360D1 (en) | 1981-06-16 | 1985-10-24 | Choay Sa | Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation |
| AU6427596A (en) * | 1992-04-14 | 1996-10-31 | Alfred Maximillian Stessl | A boat hull |
| TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| DK0951282T3 (da) * | 1996-12-20 | 2008-07-14 | Pfizer | Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister |
| GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
| AU6427599A (en) * | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for stimulating bone formation |
| CA2346038A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
-
2000
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-11-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en not_active Ceased
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-11 EP EP00311034A patent/EP1110949B1/en not_active Expired - Lifetime
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active Expired - Fee Related
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
-
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
-
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925L/no not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002555A0 (en) | EP4 Receptor selective agonists in the treatment of osteoporosis. | |
| WO2002042268A3 (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| TR200200843T2 (tr) | İşemi'nin Tedavisi için olan bileşikler | |
| TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
| PT1305286E (pt) | Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
| DK1075259T3 (da) | Hidtil ukendte fedtsyreanaloger til behandling af diabetes | |
| TR200102910T2 (tr) | èeker artìklarìyla ikame edilmiç 1,4-benzotiyazepin-1,1-dioksid trevleri | |
| TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
| NO991206L (no) | Benzamidinderivater substituert med sykliske aminosyre- eller sykliske hydroksysyrederivater, og deres anvendelse som antikoagulanter | |
| BR9913255A (pt) | Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto | |
| BRPI0413200A (pt) | método para tratamento de endometriose | |
| DE69922703D1 (de) | Ureido-thiobuttersäurederivate als ppar-agonisten | |
| WO2004050620A3 (en) | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | |
| DK0888271T3 (da) | Benzamidinderivater substitueret med aminosyre- og hydroxysyrederivater og deres anvendelse som antikoagulerende midler | |
| BR0100381A (pt) | Tratamento de osteoporose com agonistasseletivos do receptor ep/2/ep4 | |
| BRPI0417621A (pt) | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea | |
| ATE359242T1 (de) | Flüssiger abbindebeschleuniger für portlandzement enthaltende zusammensetzung | |
| WO2006000577A3 (en) | Lxr agonists to promote bone homeostasis | |
| AR038332A1 (es) | Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion | |
| AU2003251729A1 (en) | Use of antibodies against flt-1 for the treatment of osteoporosis | |
| PL366988A1 (en) | Gelling sugar and method for producing the same | |
| DE60017793D1 (de) | Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes | |
| HUP0002727A2 (hu) | Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával |